The Hematologic Malignancies Market is projected to grow from USD 72,200.85 million in 2024 to USD 128,481.41 million by 2032 ...

Servier Canada is pleased to announce that VORANIGO® (vorasidenib tablets) is now publicly reimbursed in Ontario under the province's Funding Accelerated for Specific Treatments (FAST) program. The ...

One woman shares her story of hope living with a rare and aggressive brain cancer. Jennifer's* story begins in a small town ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the best small-cap stocks with huge growth potential. Nuvation Bio Inc.

New long-term data highlights the effectiveness and safety of ivosidenib with azacitidine for treating IDH1-mutated AML, improving patient outcomes significantly. New long-term follow-up data from the ...

Abstract: Brain glioma is a very serious disease and the mutation status of isocitrate dehydrogenase (IDH) is an important factor in its diagnosis. There is a clear link between the prognosis of ...

Isocitrate dehydrogenase (IDH)-mutant gliomas happen when IDH1 or IDH2 changes create an abnormal enzyme. This mutant enzyme makes D-2 hydroxyglutarate (D-2HG), which encourages tumor growth.

A study has identified a new target for Group-3 medulloblastomas. Medulloblastomas are one of the most common childhood brain cancers. Particularly, Group-3 medulloblastomas are aggressive and ...

Backgroud: Metabolic and ventricular remodeling are early events of pressure overload that lead to heart failure. Metabolic remodeling is characterized by an imbalance between the tricarboxylic acid ...